GlassScriptPhysician profile
Thomas Hayth
NPI 1174091144
$3,470.44
in general payments reported to CMS, 2019-2025
10 companies · $952 in 2025
The $952 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $203 · 2024: $2,197 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111 · Travel and Lodging: $891 · Education: $200 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.13 |
| Travel and Lodging | $891.09 |
| Education | $199.98 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,969.14 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $664.85 | 2022-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $319.04 | 2023-2025 | |
| Axsome Therapeutics, INC. | $140.12 | 2023-2025 | Sunosi |
| Vanda Pharmaceuticals INC. | $101.13 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $98.15 | 2024-2025 | Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $81.20 | 2023-2024 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $41.12 | 2023-2024 | Lumryz |
| Neurocrine Biosciences, INC. | $34.70 | 2025 | |
| Lilly USA, LLC | $20.99 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hayth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.